Cancer Clinical Trials in Africa—An Untapped Opportunity: Recommendations From AORTIC 2019 Conference Special Interest Group in Clinical Trials

Abiola Ibraheem, MD1; Colin Pillai, MD2,3; Ifeoma Okoye, MD4,5; J. Joshua Smith, MD, PhD6; Diane Reidy-Lagunes, MD7; Grace Macaulay, MD8; and Olusegun Alatise, MD9

Cancer is now a formidable health care burden in sub-Saharan Africa (SSA) due to lifestyle westernization and longer life expectancy. The exponential increase in cancer incidence coupled with high mortality rate is not comparable with that seen in westernized countries. To address global cancer disparity, globalization of cancer clinical trials to involve sub-Saharan Africa can serve as a platform where innovative targeted therapies can be made available to patients in the environ. In the 2019 African Organization for Research and Training in Cancer (AORTIC) conference held at Maputo, Mozambique, a group of clinical trialists spanning across multiple continents highlighted the opportunities in Africa for the conduct of cancer clinical trials. The secondary purpose of the meeting was to address the belief that Africa was incapable of conducting interventional cancer trials but showed the in-continent strengths, such as available capacities, trained local clinical trialists with clinical trial experiences, clinical trial consortia, local capabilities, mapping out logistics, ethical consideration, political will, real-time benefits of clinical trials to clinical practice, and future directions for trials.

INTRODUCTION
There has been an increase in globalization of clinical trials in the beginning of the 21st century, driven by multiple factors including the need to access wider pools of study participants, reduce research timelines, and address the global burden of disease. Over the past decades, there has been an expansion of cancer clinical trials from resource rich-countries to involve other countries with lesser resources. Factors cited for globalization of cancer clinical trials include the ability to reduce operational costs, access to treatment-naive patients, growth of the health care market size, the increase of research capacity, and demands for local patient data by regulatory authorities (notably those in Asia). The benefits of globalizing cancer trials have resulted in increased geographic dispersion of clinical development operations, provided a lever for governments to negotiate drug prices, improved availability and experience with new therapies to patients with cancer and their attending clinicians, and improved health care systems. Sadly, most African countries (except for few countries such as Egypt and South Africa) have been left out of these globalization efforts. The participation of African countries in clinical trials is arguably the most proactive route to bringing innovative cancer therapies and functional infrastructure to the continent. Some of the reasons cited for excluding Africa in clinical trials include low resources, poor infrastructure, limited expertise, concerns about data quality and integrity, and post-trial access of the trial medications to the participants and the population after the trial is completed. It is a reality, however, that these reasons have not prevented the conduct and success of infectious diseases clinical trials such as HIV and/or AIDS and tuberculosis. The insights in population-level treatment regimens for HIV/AIDS studies conducted in Africa have improved care for people living with this disease worldwide and the inclusion of Africa would be advantageous to the sponsors of clinical trials (eg, the pharmaceutical industry).

To that end, the African Organization for Research and Training in Cancer (AORTIC) met in Maputo, Mozambique, in November 2019 to discuss effective approaches to conducting cancer clinical trials in Africa and the opportunities that the continent provides as a hub for cancer clinical trials. The purpose of this paper is to summarize the key presentations and to present recommendations that arose from the meeting to invite further collaboration.

THE CURRENT STATUS OF ONCOLOGY CLINICAL TRIALS IN AFRICA
Although Africa has approximately 15% of the world’s population, only an estimated 2% of global clinical
trials are conducted in Africa. A review of the National Institutes of Health trial repository ClinicalTrials.gov shows that 736 clinical trials are conducted in Africa, out of which only 26 are cancer-related interventional trials and only six of these trials are conducted in countries with predominantly Black patients.

The apparent noninclusion of African patients is multifactorial and includes cultural beliefs, lack of trust, and concerns around exploiting vulnerable populations. It is interesting to note that under-representation of African patients is also seen in the global north as evidenced by advocacy efforts to diversify clinical trials and improve representation of racial and ethnic minority groups. It is important to advocate for the inclusion of African patients in cancer clinical trials because these patients are more likely to present at a later stage or have a poorer outcome.

Africa’s research landscape is beginning to change because of increase in economic development, Westernized lifestyle, and the rising incidence of noncommunicable diseases such as cancer. African countries are underrepresented in cancer research partly because of lack of research resources, although it is widely known that research-led solutions are impactful on the high rates of mortality. Organizations such as AORTIC and ASCO are building bridges to conquer cancer and reduce disparities in patient outcome through educational programs and partnership with African countries. In addition, regulatory agencies such as the US Food and Drug Administration have convened discussion meetings and issued position papers and guidance documents in an effort to address this disparity.

GOOD CLINICAL PRACTICE, ETHICS, AND REGULATORY ISSUES IN AFRICA

Several individual regulatory bodies have joined regional harmonization efforts to ensure that the conduct of clinical trials in African countries adheres with international good clinical practice and ethical standards. For example, the Pan African Clinical Trials Registry has built a platform to register trials and improve transparency. The African Vaccines Regulatory Forum (AVAREF), established in 2006, is a pan-African network that provides clinical trial oversight and other capacity development activities to increase access to safe and effective medical products. AVAREF improves collaborative networks and strategic alliances by promoting efficient clinical trial platforms, shared best practices, and templates for clinical trial assessment procedures. The African Medicine Agency serves as the continental regulatory body that ensures harmonized and strengthened regulatory systems by governing the regulation of medicines and medical products in Africa.

In Nigeria, to address Good Clinical Practice, The Association for Good Clinical Practice in Nigeria in collaboration with the National Agency for Food and Drug Administration and Control aimed at increasing the participation of African indigenous scientists in global clinical trials to build capacity. Regulatory Resources For Africa is a collaboration among regulatory bodies in 34 African countries for clinical trial application and harmonization. Although some agencies have internal capacity for scientific and ethical review, in most cases where there is no capacity for review, assessments are outsourced to academia.

The adherence to the international guidelines on ethical conduct will protect vulnerable populations and encourage sponsors to study, register, market, and ensure affordable access to state-of-the-art new therapies in African countries.

DESIGN, CONDUCT, AND ANALYSIS OF PHASE I-IV CLINICAL TRIALS IN AFRICA

Phase I trials representing the important translation from preclinical to human use establishes safety, pharmacokinetics, and early assessment of dose response. These have been classically used for both cancer and noncancer drugs in diverse global settings. In Africa, historically, there are very few phase I studies, but this is changing with some phase I infectious disease interventional clinical trials reported for antimalarial drugs, Ebola vaccines, and HIV/AIDS vaccines. Although very few phase I cancer clinical trials are reported in Africa (eg, colon cancer phase I studies), the fact that Phase I trials...
have been conducted in Africa indicates that the scientific skills and infrastructure already exists and can be expanded in future.

Phase II trials demonstrate further evidence of safety and efficacy in patients before moving to larger phase III trials that evaluate the efficacy of a drug based on recognized clinical end points. For example, in Mali, a single-blind, randomized primarqueine study in 80 patients used infectivity before and after treatment as the primary efficacy end point.24 There are few ongoing phase II oncology trials in Africa, eg, an investigator-initiated Phase II breast cancer clinical trial in Nigeria where the response rate of subcutaneous trastuzumab is being assessed.25 This lends evidence that Phase II trials can be accomplished in Africa.

Phase III studies confirm therapeutic efficacy observed in phase II trials in a larger number of patients and assess additional clinical questions (eg, comorbidities to monitor during treatment, dosage adjustment, length of treatment, profiles of responder patients, and drug interactions). Phase III studies require large sample sizes and long study durations and are therefore more expensive. Some have argued that Africa provides a low-cost opportunity with large patient populations that can ensure rapid accrual with increased incidence of the disease.26 These trials need to align with the national health strategies and burden of disease priorities. These studies should have inclusion and exclusion criteria that are not too vague (heterogeneous) or too aggressive (not translatable) to optimally generate data that are more representative and informative of patients of African Ancestry. Strong and informed regulatory and government agencies can help facilitate this.

DRUG DISCOVERY AND DEVELOPMENT IN AFRICA: EXPANSION THROUGH COLLABORATIONS

The people in the 54 sovereign countries in Africa are diverse in physiologic and genetic makeup, culture, and the intrinsic and extrinsic factors that ICH-E527 describes, all of which could be used positively in clinical drug development to benefit global patients. Drug development on endemic infectious diseases such as malaria, tuberculosis, and HIV/AIDS illustrates the profound impact that drug development could have in Africa. The lessons learnt from infectious disease drug development could be the platform to increase oncology drug development and participation in global oncology trials. As an illustrative example of the missed opportunity, a search of ClinicalTrials.gov showed that out of the over 1,000 clinical trials using pembrolizumab in all cancers, 16 were in Africa; as mentioned above, the majority of these were in South Africa (15) and Egypt (one).28

Africa’s research capabilities and infrastructure are expanding through collaborations with international organizations such as The European and Developing Countries Clinical Trials Partnership, which was created in 2003 to develop capabilities for phase II or III trials in sub-Saharan Africa. The Swiss Tropical and Public Health Institute has developed TRREE,29 a web site that provides ethical guidelines, training, and access to free distance learning programs and resources to support studies conducted in Africa.

The readiness of Africa has been facilitated through the capacity-building investments mentioned above and additionally in programs such as Welcome Centre for Anti-Infectives Research and the Holistic Drug Discovery and Development Centre. The Holistic Drug Discovery and Development Centre put its first African drug MMV390048 through phase I and II clinical trials as a promising agent working on all stages of the malaria parasite's life cycle.30,31

Capacity building in Africa has been extended beyond drug development to molecular diagnostics in infectious diseases, for example, using Cepheid’s platform to improve the diagnosis of HIV and tuberculosis.32 This is being extended gradually into oncology with partnerships between non-governmental organizations such as the Max Foundation and pharmaceutical companies that are providing imatinib for the treatment of chronic myelogenous leukemia with monitoring of the patient using the BCR-ABL GeneXpert Ultra.33

CONDUCTING CLINICAL TRIALS IN AFRICA AND THE OPPORTUNITIES TO SCALE UP

To scale up oncology clinical trials in Africa, we have identified seven strategic areas that must evolve in many countries to correct the current low number of cancer clinical trials in Africa.

1. Development of human capacity in conducting clinical trials:

In 2019, to address the extreme limitation in human capacity, The African Research Group for Oncology (ARGO),34 supported by the US Civilian Research and Development Foundation, funded and organized a training program on clinical trials in Nigeria for 50 early career researchers. Pre-and post-training assessment revealed a significant rise in knowledge. The African Clinical Trials Consortium35 organizes monthly webinars on different aspects of clinical trials with the aim of building a critical mass of clinical trialists in Africa.35 These initiatives will develop the confidence of clinical trial sponsors and funding agencies to invest further in the continent. We encourage more of such opportunities to expose and train early career researchers by using stratified training (basic and advanced courses) and hands-on workshops. In addition to training early career researchers, it is necessary to train mentors on how to provide necessary support for these young researchers. We suggest that the AORTIC and other international organizations partner with societies and training institutions to organize capacity development training.
2. Increasing visibility of the research infrastructure for interventional cancer clinical trial in Africa:

The African Academy of Sciences recently launched the Clinical Trials Community project, a database of African clinical trial sites and capabilities as an open-access, web-based, up-to-date system with profiles of African clinical trial sites, and the associated ecosystem of regulatory and ethics committees for clinical trials on the continent. This project has impressive local and international support from private and public sector partners including the Bill & Melinda Gates Foundation, the US National Institutes of Health, the biopharmaceutical industry, product development partners, clinical researchers, and African regulatory agencies. The database is expected to enable an increase in investment in clinical trials on the continent.

The following areas have been identified as gaps that the project will seek to address.

- Up-to-date information on country-specific clinical trial regulatory guidelines is part of the platform under a collaboration with AVAREF and supported by regulatory agencies from the member states.
- Up-to-date information on key clinical trial site capabilities and gaps will be critical for sponsors to target their more detailed subsequent trial-specific feasibility assessments.
- A graphical overlay of disease burden data onto the location of existing clinical trial sites will help to simultaneously identify where trials could be located and to target capacity and infrastructure development programs.
- Early prioritization of diseases and therapeutic areas of mutual interest to Africa, the African Academy of Sciences, and its partners such as tuberculosis, sickle cell disease, several oncology indications, and Lassa fever.

To better describe the clinical trial infrastructure for oncology trials, Bio Ventures for Global Health developed a complementary initiative to profile cancer clinical trial sites and describe available technologies and infrastructures in their sites. African countries and institutions have varying degrees of sophistication in their research infrastructure for interventional clinical trials. It is expected that research infrastructure should include major scientific equipment, software as well as knowledge-based resources with associated technical support.

3. Strengthen the African trials consortia:

The formation of consortiums in Africa will offer the ability to rapidly recruit many patients into a trial while also allowing for collaboration among African clinical trialists. A few such consortia are beginning to emerge, some of which have been recognized by the US National Cancer Institute, eg, ARGO working on colorectal and breast cancers; Prostate Cancer Transatlantic Consortium and Men of African Descent and Cancer of the Prostate working on prostate cancer; and the Global Surgical Outcome Collaboration working on surgical outcomes in oncology. Global Surgical Outcome Collaboration has successfully conducted and is conducting clinical trials in Africa, which include pragmatic multicenter FACTor trials randomized controlled trials testing measures to reduce surgical site infection in low- and middle-income countries (FALCON trial) and a cluster randomized trial of sterile glove and instrument change at wound closure to reduce surgical site infection (CHEETAH trial). Some international consortia involve African and European countries, eg, one being led by the Kintampo Health Research Centre in Ghana and involving partners from the KEMRI-Wellcome Trust Research Programme in Kenya, the Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou in Burkina Faso, and the London School of Hygiene and Tropical Medicine in the United Kingdom. This consortium focuses on the delivery of health care to children in low-resource settings.

4. Establishment of biorepositories:

Most drug clinical trials require collection of biologic fluid and tissue samples and require careful protocols for sample processing and transportation including well-maintained in-country biorepositories for storage. Analysis of these tissue samples enable patient stratification, prognostic assessments via biomarker developments, and pharmacologic studies that would be impractical to perform by acquiring large numbers of trial participants. Few biobanks are emerging, and these include H3A biorepositories in Uganda, Steellenbosch, and Cape Town, and 54 Gene and ARGO biobanks in Nigeria. Start-up costs for establishing a biobank is cost intensive but may be cost saving if centralized, given that longer-term maintenance costs also need to be factored in. More of such should be established and should be supported by all researchers in sub-Saharan Africa.

5. The provision of funds for pilot studies:

Before launching a big trial, preliminary feasibility assessment or trials is encouraged to build local research culture. In this regard, ARGO introduced grants to fund research initiative of indigenous early career researchers in 2015. Since its introduction, six researchers have benefited from this opportunity.

6. Secure protected time for African researchers:

Clinical and basic researchers in Africa have no guaranteed protected time as they are expected to be involved in clinical and teaching assignments in addition to administrative duties. There should be increased advocacy to policymakers, opinion leaders, and mentors on possible innovative ways to ensure protected time for researchers.

7. Strengthen health authority and government agency clinical trial approval processes:

Different countries in Africa have well laid-out sets of standard regulatory and institutional review board (IRB) guidelines for conducting a clinical trial. Puppalwar et al reviewed some of the guidelines for some of the African countries. Good understanding of the guidelines can help to reduce bottleneck encountered in getting the appropriate approvals.

In conclusion, Africa needs to conduct more clinical trials to reverse the dismal statistic of hosting < 2% of global clinical trials in Africa.
AFFILIATIONS
1Section of Hematology Oncology, University of Chicago, Chicago, IL
2Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa
3CP+ Associates GmbH, Basel, Switzerland
4Department of Radiology, College of Medicine, University of Nigeria,Nsukka, Nigeria
5University of Nigeria Centre for Clinical Trials, University of Nigeria Teaching Hospital, Enugu. Ituku Ozalla, Nigeria
6Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
7Gastrointestinal Oncology Service, Department of Medicine, Memorial Department of Medicine, Weill Cornell Medical College, New York, NY
8Medical Scientific Affairs and Strategy (Oncology), Cepheid Oncology, Sunnyvale, CA
9Division of Gastrointestinal/Surgical Oncology, Department of Surgery, Obafemi Awolowo University/Teaching Hospitals, Ile-Ife, Nigeria

CORRESPONDING AUTHOR
Olusegun Alatise, MD, Division of Gastrointestinal/Surgical Oncology, Department of Surgery, Obafemi Awolowo University/Teaching Hospitals, PMB 5538, Ile-Ife, Nigeria; e-mail: segunatalishe@yahoo.co.uk.

AUTHOR CONTRIBUTIONS
Conception and design: Abiola Ibraheem, Colin Pillai, Ifeoma Okoye, J. Joshua Smith, Diane Reidy-Lagunes, Grace Macaulay, Olusegun Alatise
Financial support: Abiola Ibraheem
Administrative support: Abiola Ibraheem, Ifeoma Okoye
Provision of study materials or patients: Abiola Ibraheem, Ifeoma Okoye
Collection and assembly of data: Abiola Ibraheem, Colin Pillai, Ifeoma Okoye, J. Joshua Smith, Diane Reidy-Lagunes, Grace Macaulay, Olusegun Alatise
Data analysis and interpretation: Abiola Ibraheem, Colin Pillai, Ifeoma Okoye, Diane Reidy-Lagunes, Grace Macaulay, Olusegun Alatise
Manuscript writing: All authors
Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.

Colin Pillai
Employment: Roche, CP+ Associates GmbH
Leadership: Clinical Research Management Ltd (ACE Research), Nairobi, Kenya
Stock and Other Ownership Interests: Novartis, Alcon, Roche
Consulting or Advisory Role: Johnson & Johnson/Janssen

Ifeoma Okoye
Stock and Other Ownership Interests: Safety Molecular Pathology Laboratory

J. Joshua Smith
Consulting or Advisory Role: Guardant Health

Diane Reidy-Lagunes
Honoraria: Novartis
Consulting or Advisory Role: Lexicon, Advanced Accelerator Applications
Research Funding: Novartis, Ipsen, Merck

Grace Macaulay
Employment: MedImmune, Cepheid/Danaher

Stock and Other Ownership Interests: MedImmune

No other potential conflicts of interest were reported.

REFERENCES
1. Getz K: CRO contribution to drug development is substantial and growing globally. Impact Rep 8:1-4, 2006
2. Shah S: Globalization of clinical research by the pharmaceutical industry. Int J Health Serv 33:29-36, 2003
3. Olliaro PL, Vijayan R, Inbasegaran K, et al: Drug studies in developing countries. Bull World Health Organ 79:894-895, 2001
4. Barton BL: International conference on harmonization-good clinical practices update. Drug Inf J 32:1143-1147, 1998
5. Goldbrunner T, Doz Y, Wilson K, et al: The well-designed global R&D network. Strategy and Business 43, 2006
6. Moon S, Bermudez J, Hoen Et: Innovation and access to medicines for neglected populations: Could a treaty address a broken pharmaceutical R&D system? PLoS Med 9:e1001218, 2012
7. Tinto H, Valea I, Sorgho H, et al: The impact of clinical research activities on communities in rural Africa: The development of the Clinical Research Unit of Nanor (CRUN) in Burkina Faso. Malar J 13:113, 2014
8. Bacci ML: A Concise History of World Population. Hoboken, New Jersey, John Wiley & Sons, 2017
9. Bairu M, Chin R: Global Clinical Trials Playbook (ed 1). Amsterdam, the Netherlands, Elsevier 9, 2020
10. Search of: Black | Cancer
11. Barreto ML: Health research in developing countries. BMJ 339:b4846, 2009
12. Rubagumya F, Mitera G, Ka S, et al: Choosing wisely Africa: Ten low-value or harmful practices that should be avoided in cancer care. JCO Glob Oncol 6:1192-1199, 2020
13. Coakley M, Fadiran EO, Parrish LJ, Griffith RA, Weiss E, Carter C: Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials. J Womens Health (Larchmt). 2012 Jul; 21(7):713-6. doi: 10.1089/jwh.2012.3733

14. Pan-African Clinical Trials Registry: WHO recognised clinical trials registry in Africa, in European Union (ed): South Africa, EDCTP, 2017

15. ICH: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Is Unique in Bringing Together the Regulatory Authorities and Pharmaceutical Industry to Discuss Scientific and Technical Aspects of Pharmaceuticals and Develop ICH Guidelines. Geneva, Switzerland, OSEM, 2017

16. WHO Africa Publication. African Vaccine Regulatory Forum (AVAREF) - Strategy and Guidance for Emergency Preparedness, 2020

17. Regulatory Resources for Africa: Harmonizing Regulatory Resources for Africa. South Africa, Africa IPAS, 2017

18. Hansen AR, Graham DM, Pond GR, et al: Phase 1 trial design: Is 3+ 3 the best? Cancer control 21:200-208, 2014

19. Chilengi R, Juma R, Abdallah AM, et al: A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. Malar J 10:1-9, 2011

20. Agnandji ST, Huttner A, Zinser ME, et al: Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 374:1647-1660, 2016

21. Barouch DH, Tomoka FL, Wegmann F, et al: Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 392:232-243, 2018

22. Abdellatif AAH: Targeted polymeric nanoparticles loaded with cetuximab and decorated with somatostatin analogue to colon cancer. ClinicalTrials.gov, 2020

23. Dicko A, Rohe ME, Diawara H, et al: Efficacy and safety of primaquine and methylene blue for prevention of plasmodium falciparum transmission in Mali: A phase 2, single-blind, randomised controlled trial. Lancet Infect Dis 18:627-639, 2018

24. Ntekim AI, Ibraheem A, Sofoluwe AA, et al: ARETTA: Assessing response to neoadjuvant taxotere and subcutaneous trastuzumab in Nigerian women with HER2-positive breast cancer: A study protocol. JCO Glob Oncol 6:983-990, 2020

25. McMichael C, Waters E, Volmink J: Evidence-based public health: What does it offer developing countries? J Public Health 27:215-221, 2005

26. Ethnic Factors in the Acceptability of Foreign Clinical Data E5(R1) (ed step 4 version), ICH Harmonised Tripartite Guideline, 1998

27. Clinical Trials Community Platform | United for Africa's Health, 2021. www.ctc.africa

28. BIO Ventures for Global Health, @BIOVentures, 2021. https://bvgh.org/news-and-publications-2/

29. Nepogodiev D, Bhangu A: Pragmatic multicentre factorial randomised controlled trial testing measures to reduce surgical site infection in low-and middle-income countries: Study protocol of the FALCON trial. Colorectal Dis 23:298-306, 2021

30. Puppalwar G, Mouya M, kadhe G, et al: Conducting clinical trials in emerging markets of sub-Saharan Africa: Review of guidelines and resources for foreign sponsors. Open Access J Clin Trials 7:23-34, 2015